Ausgabe 6/2019
Inhalt (25 Artikel)
The role of PD-1/PD-L1 axis and macrophage in the progression and treatment of cancer
Jiajing Cai, Qi Qi, Xuemeng Qian, Jia Han, Xinfang Zhu, Qi Zhang, Rong Xia
Beyond a chemopreventive reagent, aspirin is a master regulator of the hallmarks of cancer
Xiao Zhang, Yukuan Feng, Xi Liu, Jianhui Ma, Yafei Li, Tianzhen Wang, Xiaobo Li
NOD1 and NOD2 of the innate immune system is differently expressed in human clear cell renal cell carcinoma, corresponding healthy renal tissue, its vasculature and primary isolated renal tubular epithelial cells
Lilli Mey, Michaela Jung, Frederik Roos, Roman Blaheta, Axel Hegele, Ralf Kinscherf, Anja Urbschat
Chemopreventive effect of Callistemon citrinus (Curtis) Skeels against colon cancer induced by 1,2-dimethylhydrazine in rats
Alejandro López-Mejia, Luis Gerardo Ortega-Pérez, Daniel Godinez-Hernández, Blanca Nateras-Marin, Esperanza Meléndez-Herrera, Patricia Rios-Chavez
ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data
Young Wha Koh, Jae-Ho Han, Seokjin Haam, Joonho Jung
Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively
Angélica María Gamboa-Cedeño, Mariángeles Castillo, Wenming Xiao, Thomas A. Waldmann, Stella Maris Ranuncolo
Molecular and cellular adaptations to exercise training in skeletal muscle from cancer patients treated with chemotherapy
Andreas Buch Møller, Simon Lønbro, Jean Farup, Thomas Schmidt Voss, Nikolaj Rittig, Jakob Wang, Inger Højris, Ulla Ramer Mikkelsen, Niels Jessen
Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration
Abdulhameed Al-Ghabkari, Deema O. Qasrawi, Mana Alshehri, Aru Narendran
IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2
Xiaodong Chen, Feng Chen, Yu Ren, Guobin Weng, Lijun Xu, Xiang Xue, Peter C. Keng, Soo Ok Lee, Yuhchyau Chen
Different statistical techniques dealing with confounding in observational research: measuring the effect of breast-conserving therapy and mastectomy on survival
Marissa C. van Maaren, Saskia le Cessie, Luc J. A. Strobbe, Catharina G. M. Groothuis-Oudshoorn, Philip M. P. Poortmans, Sabine Siesling
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy
Erlend Skaga, Ida Ø. Skaga, Zanina Grieg, Cecilie J. Sandberg, Iver A. Langmoen, Einar O. Vik-Mo
TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells
Jinfang Zhu, Weiran Liu, Chen Chen, Hua Zhang, Dongsheng Yue, Chenguang Li, Lianmin Zhang, Liuwei Gao, Yansong Huo, Chang Liu, Giuseppe Giaccone, Bin Zhang, Changli Wang
Research driving innovation: what are key factors for successful integration of translational science into oncology care concepts? 5th European Roundtable Meeting (ERTM) May 4th, 2018, Berlin, Germany
Olaf Ortmann, Julie Torode, Chris Harrison, Johannes Bruns, Ulrike Helbig, Nicolas Philippou, Stefan Schreck, Tit Albreht, Josep Borras, Julie Torode, Jan-Willem Coebergh, Chris Harrison, Johannes Bruns, Ulrike Helbig, Andreas Hochhaus, Monika Klinkhammer-Schalke, Christoph Kowalski, Margarete Landenberger, Katrin Mugele, Olaf Ortmann, Ralf Rambach
Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases
Suheil Albert Atallah-Yunes, Anis John Kadado, Gregory P. Kaufman, Jaime Hernandez-Montfort
Gastrointestinal stromal tumors (GISTs) with remarkable cystic change: a specific subtype of GISTs with relatively indolent behaviors and favorable prognoses
Anwei Xue, Wei Yuan, Xiaodong Gao, Yong Fang, Ping Shu, Chen Xu, He Li, Yifang Xu, Qi Song, Yingyong Hou, Kuntang Shen
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
Martin Schuler, Eng-Huat Tan, Kenneth O’Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih-Hsin Yang, Ki Hyeong Lee, Shun Lu, Yuankai Shi, Sang-We Kim, Janessa Laskin, Dong-Wan Kim, Catherine Dubos Arvis, Karl Kölbeck, Dan Massey, Angela Märten, Luis Paz-Ares, Keunchil Park
Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?
Vérane Achard, Sandra Jorcano, Michel Rouzaud, Lluís Escudé, Raymond Miralbell, Thomas Zilli
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia
Jorge E. Cortes, Carlo Gambacorti-Passerini, Michael W. Deininger, Michael J. Mauro, Charles Chuah, Dong-Wook Kim, Dragana Milojkovic, Philipp le Coutre, Valentin Garcia-Gutierrez, Rocco Crescenzo, Carla Mamolo, Arlene Reisman, Andreas Hochhaus, Tim H. Brümmendorf
Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma
Nidhi Gupta, Raman Kumar, Tulika Seth, Bhavuk Garg, Hem Chandra Sati, Alpana Sharma
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice
Beung-Chul Ahn, Kyoung-Ho Pyo, Chun-Feng Xin, Dongmin Jung, Hyo Sup Shim, Chang Young Lee, Seong Yong Park, Hong In Yoon, Min Hee Hong, Byoung Chul Cho, Hye Ryun Kim
Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer
Fan Lian, Wenchuan Chen, Yiming Liu, Long Shen, Wenzhe Fan, Wei Cui, Yue Zhao, Jiaping Li, Yu Wang
Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer
Peter G. Hawkins, Yilun Sun, Robert T. Dess, William C. Jackson, Grace Sun, Nan Bi, Muneesh Tewari, James A. Hayman, Gregory P. Kalemkerian, Shirish M. Gadgeel, Theodore S. Lawrence, Randall K. Ten Haken, Martha M. Matuszak, Feng-Ming (Spring) Kong, Matthew J. Schipper, Shruti Jolly
Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry)
Susanne Möbius, Thomas Schenk, Danny Himsel, Jacqueline Maier, Georg-Nikolaus Franke, Susanne Saussele, Christiane Pott, Hajnalka Andrikovics, Nora Meggyesi, Katerina Machova-Polakova, Hana Zizkova, Tomáš Jurcek, Semir Mesanovic, Renata Zadro, Enrico Gottardi, Jens Haenig, Peter Schuld, Nicholas C. P. Cross, Andreas Hochhaus, Thomas Ernst
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva
Fabinshy Thangarajah, Bernd Morgenstern, Caroline Pahmeyer, Lars Mortimer Schiffmann, Julian Puppe, Peter Mallmann, Stefanie Hamacher, Reinhard Buettner, Christina Alidousty, Barbara Holz, Andreas H. Scheel, Anne Maria Schultheis
Serum PD-1 levels measured by ELISA using Nivolumab increased in advanced RCC patients: novel approach to develop companion diagnostics for antibody therapy
Kosuke Mizutani, Kengo Horie, Taku Kato, Keita Nakane, Kyojiro Kawakami, Yasunori Fujita, Masafumi Ito